GRANIX
Peaktbo-filgrastim
BLAINJECTIONINJECTABLE
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
GRANIX (tbo-filgrastim) is tbo-filgrastim is a human granulocyte colony-stimulating factor (g-csf) produced by recombinant dna technology. First approved in 2012.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GRANIX (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) approved in 2012 for reducing the duration of severe neutropenia in cancer patients receiving myelosuppressive chemotherapy. It binds to G-CSF receptors to stimulate neutrophil proliferation and differentiation, restoring immune function in immunocompromised patients. This is a biosimilar-class biologic that operates as a growth factor replacement therapy.
$0.002BPart D
PeakProduct is at peak lifecycle stage with modest Part D spending ($2M in 2023) and 1,034 claims, suggesting a stable but niche market with limited team expansion opportunities.
Mechanism of Action
Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Started May 2015
50 enrolled
Neutropenia
Career Relevance
GRANIX currently has zero linked job openings, indicating a mature product with minimal hiring activity and limited career momentum. Roles on this product would primarily focus on defending market share in oncology settings rather than growth initiatives or innovation.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.